Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Aldeyra Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
13.2
16.3
29.8
44.4
24.7
44.9
47.3
29.5
48.2
25.7
General and administrative
5.52
6.19
9.88
12.2
9.99
11.3
15.4
13.3
11.9
9.6
Operating income
-18.7
-22.5
-39.7
-63.1
-36.4
-56.2
-62.7
-42.8
-60.1
-35.3
Interest expense
0.11
0.11
0.15
0.6
1.9
1.74
1.69
2.07
1.93
1.91
Interest income
0.1
0.26
0.95
1.54
0.29
0.19
2.35
7.32
6.19
3.32
Other non-operating income
-0
0.15
0.81
0.94
-1.61
-1.56
0.66
5.25
4.27
1.42
Pre-tax income
-38.9
-62.1
-38
-57.8
55.9
33.8
Income tax
0
0
0
-1.31
-0.48
0
0
0
0
0
Net income
-18.7
-22.3
-38.9
-60.8
-37.6
-57.8
-62
-37.5
-55.9
-33.8
EBITDA
-18.7
-22.5
-39.6
-63
-36.4
-56
-62.4
-42.5
-59.9
-35
EPS, basic
-1.65
-1.40
-1.79
-2.24
-1.11
-1.07
-1.06
-0.64
-0.94
-0.56
EPS, diluted
-1.65
-1.40
-1.79
-2.24
-1.11
-1.07
-1.06
-0.64
-0.94
-0.56
Shares, basic (weighted)
11.4
15.9
21.7
27.1
34
54
58.4
58.9
59.5
60.1
Shares, diluted (weighted)
11.4
15.9
21.7
27.1
34
54
58.4
58.9
59.5
60.1
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
12
20
47.4
44.4
77.9
230
144
143
54.5
70
Short-term investments
46.2
28.9
0
0
29.9
0
46.6
0
Other current assets
0.22
1.02
1.17
1.8
5.2
0.03
3.24
0
0
1.74
Total current assets
25.1
44
94.8
75.2
83.1
233
181
148
104
71.8
Property, plant and equipment
0.06
0.04
0.24
0.15
0.06
0.03
0.02
0.01
0
0
Lease right-of-use assets
0.2
0.23
0.35
0.25
0.51
0.27
0.28
Total assets
25.2
44.2
95.1
75.5
83.4
233
181
148
105
72.1
Accounts payable
0.28
1
3.05
0.81
0.38
1.02
0.13
1.34
0.18
0.16
Accrued liabilities
1.95
2.24
5.42
11.9
8.13
10.5
14.1
5.54
12.1
6.12
Deferred revenue
0
6
6
Short-term debt
0.08
0.12
0.91
15.1
0.03
15.2
Total current liabilities
2.3
3.35
8.47
12.9
12.4
11.8
15.4
22.3
18.6
27.8
Long-term debt
1.24
1.22
14.5
11.4
15.5
14.9
0
15
0
Lease liabilities
0
0
0.13
0
0.27
0
0
Total liabilities
3.54
4.57
8.47
27.4
23.8
27.4
30.3
28.5
33.6
27.8
Total debt
1.4
1.4
16
16
16
16
16.3
15.3
15.3
15.3
Paid-in capital
98.9
139
225
247
296
500
508
514
521
528
Retained earnings
-77.3
-99.6
-139
-199
-237
-295
-357
-394
-450
-484
Other comprehensive income
0
-0.02
-0.01
0.01
0
0
-0.1
0
0.04
0
Shareholders' equity
21.6
39.6
86.6
48.1
59.5
206
151
120
71
44.3
Total equity
21.6
39.6
86.6
48.1
59.5
206
151
120
71
44.3
Total liabilities and equity
25.2
44.2
95.1
75.5
83.4
233
181
148
105
72.1
Shares outstanding
12.6
19.1
26.2
28.7
38.7
58.1
58.6
59.2
59.6
60.2
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-18.7
-22.3
-38.9
-60.8
-37.6
-57.8
-62
-37.5
-55.9
-33.8
Depreciation and amortization
0.04
0.04
0.07
0.1
0.06
0.26
0.26
0.26
0.25
0.25
Stock-based compensation
2.76
2.71
4.14
8.08
7.08
7.11
8.29
5.75
7.97
6.09
Deferred income tax
-1.31
-0.48
0
Change in payables
-0.58
0.73
2.05
-2.85
-0.43
0.64
-0.89
1.2
-1.16
-0.02
Cash from operations
-15.1
-19.2
-29.9
-45
-37.5
-42.6
-56.6
-30.3
-43.2
-33.3
Capital expenditures
-0.01
-0.02
-0.26
-0.01
-0.01
-0.02
0
Purchases of investments
-5.78
0
-92.9
0
-96.9
-40.3
Sales and maturities of investments
15.8
24.9
36.7
75.6
34.8
0
63
30
52
88
Cash from investing
-0.23
-10.2
-23.3
18.5
29
-0.01
-30
30
-44.9
47.7
Debt issued
14.5
Stock issued
12.6
37.5
81.8
7.89
40.7
190
0
0.19
0.35
1.1
Cash from financing
12.7
37.4
80.5
23.6
41.9
194
1.22
-1.27
-0.17
1.12
Net change in cash
-2.63
8.01
27.3
-2.93
33.4
152
-85.4
-1.6
-88.3
15.5
Free cash flow
-15.2
-19.2
-30.1
-45
-42.6
-56.7
-30.3
Interest paid
0.08
0.09
0.09
0.24
1.39
1.34
1.34
1.7
1.75
1.69
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.21 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-60.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-48.5%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-37.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-33.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-5.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-31.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-26.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-2.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
12.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.91x
Current assets / current liabilities.
Quick ratio
4.67x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.67x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.00x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
0.0%
Total debt / total assets.
Liabilities / assets
20.3%
Total liabilities / total assets.
Net debt
-$45.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.37
Cash from operations / diluted weighted shares.
Book value per share
$0.63
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.92x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.92x
Market cap / tangible book value, when positive.
Earnings yield
-31.7%
Net income / market cap (the inverse of P/E).
Was Aldeyra Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $33.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.